Table 1 Patient demographics

ALL (N = 20)

Gender (M/F)

11/9

Median age (range)

35 (13–62) years

MIC type (C/PB/EPB/T)

6/10/1/3

AML (N = 20)

Gender (M/F)

9/11

Median age (range)

41.5 (20–72) years

FAB type (M1/M2/M4/M5)

3/14/2/1

CLL (N = 61)

Gender (M/F)

44/17

Median age (range)*

65 (37–91) years

Rai stage (<2/≥2)*

37/20

Median lymphocyte count (range)*

18.5 (10–236) × 10⁹/L

High-risk [del(17p)/trisomy 12]‡

1/7

Low-risk [del(13)/normal karyotype/ other karyotype abnormalities]‡

7/16/6

CML (N = 11)

Gender (M/F)

7/4

Median age (range)

41 (22–87) years

Chronic phase

11

MM (N = 95)

Gender (M/F)

37/58

Median age (range)

62 (29–91) years

Ig type (G/A/D/LC/NS)

57/23/3/11/1

ISS stage (I/II/III)†

16/36/27

NHL (N = 68)

Gender (M/F)

38/30

Median age (range)

60.5 (17–92)

Ann Arbor stage (I/II/III/IV)^

3/4/4/18

Type (ALCL/ AITL/ PTCL,NOS/ NK-T/ FL/ MZL/ MCL/ DLBCL)

2/ 4/ 9/ 8/ 21/ 7/ 2/ 15